The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of RO4929097 Notch gamma-secretase inhibitor in metastatic melanoma: SWOG S0933.
Kim Allyson Margolin
Honoraria - Roche/Genentech
Research Funding - Roche/Genentech
James Moon
No relevant relationships to disclose
Bruce G. Redman
No relevant relationships to disclose
Tarek Chidiac
No relevant relationships to disclose
Megan Othus
No relevant relationships to disclose
Antoni Ribas
Consultant or Advisory Role - Amgen; Celgene; GlaxoSmithKline; Millennium; Roche/Genentech
Honoraria - Amgen; Celgene; GlaxoSmithKline; GlaxoSmithKline; Millennium; Roche/Genentech
Lawrence E. Flaherty
Consultant or Advisory Role - Roche/Genentech
Honoraria - Roche/Genentech
Research Funding - Roche/Genentech
Vernon K. Sondak
Consultant or Advisory Role - Merck
Honoraria - Merck
Thomas Gajewski
Consultant or Advisory Role - Roche/Genentech
Research Funding - Roche/Genentech